Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management-Reference-Cited by-同舟云学术

Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management

Published:2021-07-24 Issue:4 Volume:88 Page:741-751
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Bellesoeur Audrey,Gataa Ithar,Jouinot Anne,Mershati Sarah El,Piketty Anne-Catherine,Tlemsani Camille,Balakirouchenane David,Monribot Anthia,Vidal Michel,Batista Rui,de Percin Sixtine,Villeminey Clémentine,Alexandre Jérôme,Goldwasser François,Blanchet Benoit,Boudou-Rouquette Pascaline,Thomas-Schoemann Audrey^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04311-4.pdf

Reference46 articles.

1. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: Results of a phase III randomized multicenter clinical trial. J Clin Oncol 34(8):786–793

2. Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387(10028):1629–1637

3. Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT et al (2011) Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 12(11):1045–1052

4. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P et al (2009) Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 27(19):3126–3132

5. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL et al (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225. J Clin Oncol 23(4):866–873

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of potential drug–drug interaction knowledge, attitude, and practice among Egyptian hospital and community pharmacists: a cross-sectional multicenter study;Future Journal of Pharmaceutical Sciences;2024-01-29

2. Diagnostic et prise en charge de l’hypertension artérielle sous traitements anticancéreux;Archives des Maladies du Coeur et des Vaisseaux - Pratique;2023-12

3. Determination of drug–drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen;Journal of Oncology Pharmacy Practice;2023-07-24